Cargando…

Lignosulfonate Rapidly Inactivates Human Immunodeficiency and Herpes Simplex Viruses

Background: Very few studies of the antiviral potential of lignosulfonates have been published. With the aim of oral application, among various groups of natural products, the relative antiviral potency of lignosulfonate and its ability to rapidly inactivate viruses were investigated. Methods: As ta...

Descripción completa

Detalles Bibliográficos
Autores principales: Fukuchi, Kunihiko, Koshikawa, Takuro, Asai, Daisuke, Inomata, Megumi, Sakagami, Hiroshi, Takemura, Hiromu, Kanamoto, Taisei, Aimi, Hikaru, Kikkawa, Yuji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8538131/
https://www.ncbi.nlm.nih.gov/pubmed/34677485
http://dx.doi.org/10.3390/medicines8100056
_version_ 1784588431717826560
author Fukuchi, Kunihiko
Koshikawa, Takuro
Asai, Daisuke
Inomata, Megumi
Sakagami, Hiroshi
Takemura, Hiromu
Kanamoto, Taisei
Aimi, Hikaru
Kikkawa, Yuji
author_facet Fukuchi, Kunihiko
Koshikawa, Takuro
Asai, Daisuke
Inomata, Megumi
Sakagami, Hiroshi
Takemura, Hiromu
Kanamoto, Taisei
Aimi, Hikaru
Kikkawa, Yuji
author_sort Fukuchi, Kunihiko
collection PubMed
description Background: Very few studies of the antiviral potential of lignosulfonates have been published. With the aim of oral application, among various groups of natural products, the relative antiviral potency of lignosulfonate and its ability to rapidly inactivate viruses were investigated. Methods: As target cells, MT-4 cells in suspension and attached Vero cells were used for infections with human immunodeficiency virus (HIV) and human herpes simplex type-1 virus (HSV). Mock- or virus-infected cells were incubated for 3–5 days with various concentrations of test samples, and the viable cell number was determined with the MTT method. For the shorter exposure experiments, higher titers of HIV or HSV were exposed to test samples for 10 or 3 min, diluted to a normal multiplicity of infection (MOI), and applied to the cells. Antiviral activity was quantified by using the chemotherapy index. Results: In the long-exposure system, lignosulfonates showed comparable anti-HIV activity with those of AZT, ddC, and sulfated polysaccharides, and it exceeded those of hundreds of tannins and flavonoids. When the exposure time was shortened, the chemotherapeutic index of the lignosulfonates for HIV was increased 27-fold. At a physiological pH, lignosulfonate showed higher anti-HIV activity than commercial alkali-lignin, dealkali-lignin, and humic acid, possibly due to the higher solubility and purity. Conclusions: With their rapid virus-inactivation capabilities, lignosulfonates may be useful for the prevention or treatment of virally induced oral diseases.
format Online
Article
Text
id pubmed-8538131
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-85381312021-10-24 Lignosulfonate Rapidly Inactivates Human Immunodeficiency and Herpes Simplex Viruses Fukuchi, Kunihiko Koshikawa, Takuro Asai, Daisuke Inomata, Megumi Sakagami, Hiroshi Takemura, Hiromu Kanamoto, Taisei Aimi, Hikaru Kikkawa, Yuji Medicines (Basel) Article Background: Very few studies of the antiviral potential of lignosulfonates have been published. With the aim of oral application, among various groups of natural products, the relative antiviral potency of lignosulfonate and its ability to rapidly inactivate viruses were investigated. Methods: As target cells, MT-4 cells in suspension and attached Vero cells were used for infections with human immunodeficiency virus (HIV) and human herpes simplex type-1 virus (HSV). Mock- or virus-infected cells were incubated for 3–5 days with various concentrations of test samples, and the viable cell number was determined with the MTT method. For the shorter exposure experiments, higher titers of HIV or HSV were exposed to test samples for 10 or 3 min, diluted to a normal multiplicity of infection (MOI), and applied to the cells. Antiviral activity was quantified by using the chemotherapy index. Results: In the long-exposure system, lignosulfonates showed comparable anti-HIV activity with those of AZT, ddC, and sulfated polysaccharides, and it exceeded those of hundreds of tannins and flavonoids. When the exposure time was shortened, the chemotherapeutic index of the lignosulfonates for HIV was increased 27-fold. At a physiological pH, lignosulfonate showed higher anti-HIV activity than commercial alkali-lignin, dealkali-lignin, and humic acid, possibly due to the higher solubility and purity. Conclusions: With their rapid virus-inactivation capabilities, lignosulfonates may be useful for the prevention or treatment of virally induced oral diseases. MDPI 2021-10-03 /pmc/articles/PMC8538131/ /pubmed/34677485 http://dx.doi.org/10.3390/medicines8100056 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Fukuchi, Kunihiko
Koshikawa, Takuro
Asai, Daisuke
Inomata, Megumi
Sakagami, Hiroshi
Takemura, Hiromu
Kanamoto, Taisei
Aimi, Hikaru
Kikkawa, Yuji
Lignosulfonate Rapidly Inactivates Human Immunodeficiency and Herpes Simplex Viruses
title Lignosulfonate Rapidly Inactivates Human Immunodeficiency and Herpes Simplex Viruses
title_full Lignosulfonate Rapidly Inactivates Human Immunodeficiency and Herpes Simplex Viruses
title_fullStr Lignosulfonate Rapidly Inactivates Human Immunodeficiency and Herpes Simplex Viruses
title_full_unstemmed Lignosulfonate Rapidly Inactivates Human Immunodeficiency and Herpes Simplex Viruses
title_short Lignosulfonate Rapidly Inactivates Human Immunodeficiency and Herpes Simplex Viruses
title_sort lignosulfonate rapidly inactivates human immunodeficiency and herpes simplex viruses
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8538131/
https://www.ncbi.nlm.nih.gov/pubmed/34677485
http://dx.doi.org/10.3390/medicines8100056
work_keys_str_mv AT fukuchikunihiko lignosulfonaterapidlyinactivateshumanimmunodeficiencyandherpessimplexviruses
AT koshikawatakuro lignosulfonaterapidlyinactivateshumanimmunodeficiencyandherpessimplexviruses
AT asaidaisuke lignosulfonaterapidlyinactivateshumanimmunodeficiencyandherpessimplexviruses
AT inomatamegumi lignosulfonaterapidlyinactivateshumanimmunodeficiencyandherpessimplexviruses
AT sakagamihiroshi lignosulfonaterapidlyinactivateshumanimmunodeficiencyandherpessimplexviruses
AT takemurahiromu lignosulfonaterapidlyinactivateshumanimmunodeficiencyandherpessimplexviruses
AT kanamototaisei lignosulfonaterapidlyinactivateshumanimmunodeficiencyandherpessimplexviruses
AT aimihikaru lignosulfonaterapidlyinactivateshumanimmunodeficiencyandherpessimplexviruses
AT kikkawayuji lignosulfonaterapidlyinactivateshumanimmunodeficiencyandherpessimplexviruses